We are currently able to offer patients with high-risk cancer primary staging in the form of computed tomography (CT) or magnetic resonance imaging (MRI) in combination with bone scintigraphy or more modern combined methods such as positron emission tomography (PET)/CT or PET/MRI. The newest method due to its tracer is prostate specific membrane antigen (PSMA)-PET/CT.